

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

**CLINICAL TRIAL APPLICATION APPROVAL FOR
PNEUMOCOCCAL CONJUGATE VACCINE**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The board of directors of Company is pleased to announce that, the Company has received the clinical trial application approval (the “**CTA Approval**”) for its 13-valent pneumococcal conjugate vaccine (CRM197, TT as carrier proteins) (“**PCV13**”) from the National Medical Products Administration (“**NMPA**”) on April 19, 2019. The application of the CTA Approval was filed by the Company on December 29, 2018 and accepted by the NMPA on January 13, 2019.

On behalf of the board of directors

CanSino Biologics Inc.

Xuefeng YU

Chairman

Hong Kong, April 22, 2019

As at the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Dr. Zheng YIN as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive directors.